Ubs Group Ag Apellis Pharmaceuticals, Inc. Transaction History
Ubs Group Ag
- $527 Billion
- Q4 2024
A detailed history of Ubs Group Ag transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 2,586,739 shares of APLS stock, worth $46.5 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,586,739
Previous 13,500
19061.03%
Holding current value
$46.5 Million
Previous $389,000
21119.02%
% of portfolio
0.02%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding APLS
# of Institutions
298Shares Held
111MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$220 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$214 Million17.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$180 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$173 Million0.02% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$104 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $1.97B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...